[HTML][HTML] Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection

BC Fries, CP Taborda, E Serfass… - The Journal of clinical …, 2001 - Am Soc Clin Investig
BC Fries, CP Taborda, E Serfass, A Casadevall
The Journal of clinical investigation, 2001Am Soc Clin Investig
Phenotypic switching has been linked to the virulence of many pathogens, including fungi.
However, it has not been conclusively shown to occur in vivo or to influence the outcome of
infection. Cryptococcus neoformans undergoes phenotypic switching in vitro to colony types
that differ in their virulence in mice. In this study, we asked whether C. neoformans
undergoes phenotypic switching in vivo and whether this phenomenon contributes to
virulence. By using a small inoculum to preclude the introduction of variants that had already …
Phenotypic switching has been linked to the virulence of many pathogens, including fungi. However, it has not been conclusively shown to occur in vivo or to influence the outcome of infection. Cryptococcus neoformans undergoes phenotypic switching in vitro to colony types that differ in their virulence in mice. In this study, we asked whether C. neoformans undergoes phenotypic switching in vivo and whether this phenomenon contributes to virulence. By using a small inoculum to preclude the introduction of variants that had already switched during in vitro propagation, we demonstrated that in vivo switching to a mucoid phenotype occurred in two mice strains and was associated with a lethal outcome. Phenotypic switching resulted in changes of the capsular polysaccharide that inhibited phagocytosis by alveolar macrophages. This promoted a more vigorous inflammatory response and rapid demise. These data document in vivo switching in a fungus and associate this phenomenon with enhanced virulence and a lethal outcome. The importance of this finding is underscored by the increased likelihood of phenotypic switching in chronic cryptococcosis; thus this mechanism may account for the inability to eradicate the organism in immunocompromised hosts.
The Journal of Clinical Investigation